Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1

Fig. 2

MiR-1-3p attenuates prostate cancer cell lines proliferation through inducing cell cycle arrest at G0/G1 phase. LnCap and 22RV1 cells were transfected with 100 nM indicated RNAs molecules respectively for 72 h. a and b MTS assays revealed cell growth curves of both PCa cells in every 24 h. c Representative micrographs and (d) relative quantification of crystal violet-stained cell colonies analyzed by clonogenic formation. e and f flow cytometric determination of proportion of LnCap and 22RV1 cells in distinct cell cycle phases. g and h Expression of CDK2 and CDK4 mRNA in LnCap and 22RV1 cells were assessed by RT-qPCR following transfection with 100 nm miR-1-3p mimics, miR-1-3p inhibitor, or their negative controls (NC). GAPDH served as a loading control. i Western blot analysis of the relative expression of CDK2 and CDK4 in response to indicated RNAs molecules. GAPDH served as a loading control. The results were plotted as the mean ± S.D. of three independent experiments. (*P < 0.05, **P < 0.01, ***P < 0.001, # P < 0.05 and ## P < 0.01)

Back to article page